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Key Clinical Message
Here, we report the unusual case of an ulcerative colitis female patient present-
ing together with cytomegalovirus infection, pyoderma gangrenosum and a
noncaseating lung granuloma, both resistant to immunomodulatory drugs
which dramatically obtained a clinical stable remission after restorative procto-
colectomy.
Keywords
Crohn’s disease, inflammatory bowel disease, lung granuloma, pyoderma gan-
grenosum, ulcerative colitis.
Report
A 30-year-old woman with severe active left sided Ulcera-
tive Colitis (UC) (Montreal classification E2, Mayo endo-
scopic subscore 3 at the last colonoscopy), who had
already failed multiple courses of steroids and 5ASA, was
referred to our third level Gastroenterology Unit because
of rapid worsening of rectal bleeding and dyspnea of
4 days duration. Chest X-rays showed a round lesion in
inferior right lung lobe (Fig. 1). In the internal side of
the left popliteal region the patient had a purple skin
lesion (diameter 5 cm), compatible with Pyoderama
Gangrenosum (PG) (Fig. 2). Blood tests showed: WBC
count 17.160/mmc, Hb 9.9 gr/dL, C Reactive Protein –
CRP – 6.37 mg/dL, AST/ALT 54/158 U/L. Stool cultures
were negative, such as screening for hepatotropic viruses
(HAV, HBV, HCV, EBV) and for autoimmune diseases
(ANA, AMA, SMA, LKM). We started antibiotic therapy
with ciprofloxacin 200 mg bid and metronidazole
500 mg qd iv (prolonged for 14 days), and topical tacro-
limus bid for the treatment of PG. Before starting steroid
therapy we performed a High-Resolution CT, confirming
a nonhomogeneous 2.5 cm diameter lesion, close to the
Figure 1. Chest/abdominal X-rays showing a 2 cm diameter ground
lesion in inferior right lung lobe.
ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
195
pleura, with irregular borders compatible with a benign
lesion (Fig. 3). Blood cultures and fungal antigens screen-
ing were negative; serum IgM for CMV and plasma
CMV-DNA were positive. We suspected hence a CMV-
related pneumonia, causing at the same time the hepatitis
and the UC recrudescence. Ganciclovir was administered
for 21 days obtaining negative viremia; we finally started
steroid therapy with prednisone 50 mg per os once daily,
with nevertheless a poor improvement of intestinal symp-
toms. A CT chest scan performed 2 months later showed
a dimensional growth of the lung lesion (until 3 cm
diameter) and patient underwent a bronchoscopy with
broncho-alveolar lavage (BAL), which confirmed chronic
inflammatory cells infiltrate; acid-fast stain, culture, and
PCR for tuberculosis were negative, as well as molecular
test for CMV. A CT-guided biopsy was therefore per-
formed and histology showed lymphocytes, granulocyte,
and activated mesothelium, whereas immunochemistry
for Anti-keratin antobodies (AKA) was negative: these
findings were consistent with pulmonary non-necrotizing
granuloma (Fig. 4). Even if the patient had not renal or
Figure 2. Pyoderma Gangrenosum located in left popliteal region,
internal side, diameter 5 cm.
(A) (B)
(C) (D)
Figure 3. (A–D) High-resolution CT scan showing 2.5 cm diameter lesion with irregular borders in keeping with benign lesion.
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nasopharyngeal involvement, we performed a cANCA
screening (negative), excluding a Wegener’s Granulo-
matosis. Because of a further worsening in clinical condi-
tion, we started a “rescue therapy” with cyclosporine
4 mg/kg iv combined with azathioprine (AZA) 2.5 mg/
kg/day for maintenance. After a great improvement in the
first 72 h, the patient reported rapid onset of nausea and
vomiting and a moderate recurrence of UC (3–5 bloody
stools emissions, abdominal pain). AZA was therefore dis-
continued for intolerance. Giving the presence of the
refractory UC, the decision to perform a restorative total
colectomy with temporary protective ileostomy and
delayed proctectomy was taken. A rectoscopy after few
weeks showed the persistence of severe inflammation in
the rectal stump. We attempted a treatment with inflix-
imab (IFX), 5 mg/kg at week 0, week 2, and week 6,
observing only a partial improvement in intestinal dis-
ease; the patient, moreover, manifested a severe allergic
reaction, accompanied by a progressive worsening of
PG, and IFX was then discontinued. Proctectomy with
ileal pouch-anal anastomosis (IPAA) was then per-
formed. Postoperative course was regular, PG achieved
the remission in few weeks after the complete removal
of the rectum (Fig. 5) and subsequent chest CT scan
showed the concomitant resolution of the pulmonary
lesion (Fig. 6).
(A) (B)
(C) (D)
Figure 4. (A) Pulmonary parenchyma completely occupied by a chronic inflammatory reaction in the absence of necrosis; hematoxylin/eosin
(HE), (109): (B, C) Epithelioid noncaseating lung granuloma with a monocytic infiltrate consisting primarily of lymphocytes, plasma cells,
neutrophils, and some eosinophils; hematoxylin/eosin (HE), (209): (D) Ziehl–Neelsen immunostaining (109) negative for acid and alcohol-fast
bacilli.
Figure 5. Timeline of lower limb pyoderma evolution.
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Discussion
Inflammatory bowel diseases (IBD) may be associated
with extraintestinal manifestations (EIMs). Approxima-
tively, 10% to 35% of UC patient develop one or more
EIMs, mostly involving the skin (pyoderma gangrenosum
and erythema nodosum) or the hepato-biliary system
(Primary sclerosing cholangitis and autoimmune hepati-
tis) [1–5]. PG, an immune-mediated skin inflammation,
commonly occurs in 1–2% of IBD patients, whereas up
to 50% of PG patients have active IBD [6,7]. Its patho-
genesis is not completely clear, but TNFa seems to play a
role in mediating skin damage, since anti-TNFa antibod-
ies have been successfully used for its treatment [8]. Even
less is known about pulmonary lesions (PLs) in IBD set-
ting, as they are very uncommon [9,10]. We described an
unusual clinical presentation of UC and to our knowl-
edge the first case of contemporary noncaseating granulo-
matous lesion and PG resistant to immunosuppressive
therapy with complete resolution after restorative procto-
colectomy. Most of the IBD-associated lung lesions
described in literature are drug-related or granulomatous
conditions [11–14]. Necrobiotic parenchymal lung nod-
ules composed by sterile aggregates of neutrophils with
or without areas of necrosis are the most frequent report
in both UC and CD [15–19]. A possible explanation for
this association is the common embryological derivation
of respiratory and gastrointestinal epithelia from primi-
tive foregut, the so called gut-lung axis [20]. Nevertheless,
IBD-associated pulmonary lesions remain an exclusion
diagnosis: it is essential to rule out malignancies, infec-
tions (mycobacteria and CMV), associated disorders (sar-
coidosis, Wegener’s granulomatosis), and parenchymal
disease such as bronchiolitis obliterans with organizing
pneumonia – known as cryptogenic organizing pneumo-
nia [21]. Our patient was supposed at first to have a
(A) (B)
(C) (D)
Figure 6. HRCT scan made 12 months later with complete resolution of the pulmonary lesion.
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pneumonia related to CMV infection, which could ulti-
mately explain both the hepatitis and the recrudescence
of the intestinal disease. CMV reactivation in immuno-
compromised patient is suspected to be a risk factor for
the development of steroid-refractory UC, with a signifi-
cant greater colectomy rate in CMV+ patients [22,23].
CMV treatment with ganciclovir was therefore decided,
more for the signs of systemic infection than to treat pul-
monary lesion (which, moreover, did not improve). The
subsequent lung biopsy showed a noninfectious granulo-
matous inflammation, which could represent, in IBD set-
ting, a consistent lung manifestation of the intestinal
disease. Our patient featured, moreover, a contemporary
PG, a neutrophilic dermatosis affecting up to 20% of UC
patients, and usually characterized by ulcer with purple
and undermined borders (sometimes nodular), pustular,
bullous, or vegetating lesions of lower extremities [6]. We
performed an up-to-date literature review in PubMed
using the terms “pyoderma gangrenosum”, “IBD”,
“Crohn’s Disease”, “Ulcerative colitis”, “infliximab”,
“adalimumab”, “antiTNFalpha”, “pulmonary/lung lesions/
involvement”, considering case reports, case series, RCTs,
and retrospective papers published in English. Papers
without basic demographic information such as sex, age,
IBD type, and treatment were excluded. Almost 300 IBD
cases with associated PG are so far available (Table S1).
In five cases a contemporary PG and pulmonary involve-
ment in IBD patients was reported, but none of them
was associated with noncaseating lung granuloma
(Table 1). Four of five cases were UC patients, mostly
female (4/5) and young adults (mean age 39 years, range
17–53). Most of the patients were symptomatic, although
a wide range of presenting respiratory signs was present.
All the cases responded to the treatment adopted: three
recovered with steroids, one with surgery, and one with
IFX alone. Our case have a peculiar clinical course: both
gut, skin, and lung lesion were resistant to immunosup-
pression and completely resolved after restorative procto-
colectomy, supporting the idea that the presence of a
severe UC and impaired intestinal immune system had
led to a consequent dysregulation of the overall immune
system. PG, lung granulomas such as of sarcoidosis, and
UC are chronic inflammatory diseases, in which regula-
tory T cells (Treg) impairment plays a central role [24].
In normal gut, intestinal epithelial cells (IECs) act as a
functional barrier and nonprofessional antigen-presenting
cells (APCs), balancing the immune oral tolerance. In
IBD, immune oral tolerance is lost because of a global
defect in the mucosal immune system: the balance
between the barrier function (with impairment in IECs
integrity) and the innate and adaptive response is lost.
Such defects affect the epithelial-lymphocyte crosstalk and
alter the imbalance between Treg and effectors (activated
CD4+ lymphocytes), leading to a chronic inflammatory
state [25,26]. Indeed, Treg-depleted mice develop a
broad range of autoimmune diseases, confirming the
role of such lymphocyte subset in the control of T-cell-
mediated autoimmunity [27]. Eastaff-Leung et al.
described a decrease in Treg and an increase in Th17
cells in peripheral blood from IBD patients, with a lower
Treg/Th17 ratio, which is similarly perturbed in other
chronic inflammatory conditions (Juvenile Arthritis, Pri-
mary Biliary Cirrhosis, etc.) [28]. Moreover, it has been
recently demonstrated a reduction in Treg/Th17 ratio in
PG as well [29]. Our case is an example of how a local
altered environment such as of a severe UC may afflict
the overall immune system. Actually, it was demon-
strated that in UC patients colectomy cause the Treg
cells improvement with a peak around 7 days after
colectomy [30]; this increase is probably determined by
the removal of target antigens which may prevent Treg
growth, such as described above. We can therefore spec-
ulate that the increase in Treg cells caused a restoration
in the systemic T-cell-mediated global autoimmunity
control. In conclusion, our case is the first report of
contemporary UC, pulmonary noncaseating granuloma,
and PG, which nevertheless resolved only after a restora-
tive proctocolectomy. Gut is indeed the interface
between the immune system and the epithelial barrier
and behaves hence as the “keystone” on which the over-
all immune system rests. Further studies in IBD patients
with multiple EIMs are needed to help us in better
understanding such a complex crosstalk.
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Additional Supporting Information may be found in the
online version of this article:
Table S1. Literature review of IBD-associated PG, with/
without PLs.
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